Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence

• Published in: Expert review of vaccines 2024-12, Vol.23 (1), p.655-673
• Main Authors: Bawa, Samuel, Wondimu, Abrham, Postma, Maarten J, Hutubessy, Raymond, van Hulst, Marinus
• Format: Article
• Language: English
• Subjects: Cost-Benefit Analysis; Decision making; health economic evaluation studies; Humans; Immunization Programs - economics; Immunization, Secondary - economics; Measles - economics; Measles - epidemiology; Measles - prevention & control; Measles Vaccine - administration & dosage; Measles Vaccine - economics; Measles-Mumps-Rubella Vaccine - administration & dosage; Measles-Mumps-Rubella Vaccine - economics; Model-based; second measles containing vaccine (MCV2); systematic review; Vaccination - economics; Vaccination - methods
• ISSN: 1476-0584; 1744-8395; 1744-8395
• DOI: 10.1080/14760584.2024.2367451

The global measles incidence has decreased from 145 to 49 cases per 1 million population from 2000 to 2018, but evaluating the economic benefits of a second measles-containing vaccine (MCV2) is crucial. This study reviewed the evidence and quality of economic evaluation studies to guide MCV2 introduction. The systematic review of model-based economic evaluation studies was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search yielded 2231 articles, with 876 duplicates removed and 1355 articles screened, with nine studies included for final analysis. Six studies reported a positive benefit-cost ratio with one resulting in net savings of $11.6 billion, and two studies estimated a 2-dose MMR vaccination program would save $119.24 to prevent one measles case, and a second dose could prevent 9,200 cases at 18 months, saving $548.19 per case. The most sensitive variables were the discount rate and vaccination administration cost. Two MCV doses or a second opportunity with an additional dose of MCV were highly cost-beneficial and resulted in substantial cost savings compared to a single routine vaccine. But further research using high-quality model-based health economic evaluation studies of MCV2 should be made available to decision-makers. CRD42020200669.